Overview

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status:
Not yet recruiting
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC